One blood test for multiple cancers moves toward FDA review

WASHINGTON: A blood test designed to detect signals from multiple types of cancer in a single sample is moving toward a major US regulatory test, with the US Food and Drug Administration (FDA) set to convene an expert advisory panel next month to review GRAIL's Galleri multi-cancer early detection test.